SOSV, a Princeton, N.J.-based venture capital firm, closed the SOSV Select Fund, at $100m.
SOSV Select Fund is the firm’s first fund designed to invest in series B and later rounds. Limited partners include Credit Suisse, WTT Investment Ltd, Golden Vision Capital and AIFAM, along with family offices across the US, Europe, Asia and Australia.
Over the next three years, SOSV plans to tap the Select Fund to invest $2 to $5 million in 20 to 30 startups at Series B and beyond. The fund will invest exclusively in its existing portfolio, almost all of which are firms from SOSV’s startup development programs, including IndieBio, HAX, Chinaccelerator, MOX and dlab.
Led by Sean O’Sullivan, managing partner, SOSV is a global venture capital firm with over $900m in assets under management and more than 1,000 portfolio companies. The firm operates the startup development programs HAX (hard tech), IndieBio (life sciences), Chinaccelerator and MOX (cross-border growth in Asia) and dlab (blockchain), 8 general partners and a 130-person staff across seven locations in the US, Europe and Asia.
Alongside the new Select Fund, SOSV will continue to deploy capital from the $277m SOSV Fund IV, which started in 2019 and invests in companies going through its startup development programs, up to Series A.
FinSMEs
14/06/2021